Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers
Status:
Terminated
Trial end date:
2021-05-10
Target enrollment:
Participant gender:
Summary
IMCnyeso is a new biological therapy designed for the treatment of cancers which express
NY-ESO-1 and/or LAGE-1A. This is a first-in-human trial designed to evaluate the safety and
efficacy of IMCnyeso in adult patients who have the appropriate HLA-A2 tissue marker and
whose cancer is positive for NY-ESO-1 and/or LAGE-A1.